Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (221-230 of 300) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108Paul M Barr, Hongli Li, Catherine Spier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
JAMA Network Open|January 19, 2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in ChildrenAndrea C Lo, Amy Liu, Qi Liu, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
Leukemia & Lymphoma|June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphomaDanielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood|February 3, 2023
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphomaJuan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, et al.
Pageof 30

Showing results (221-230 of 300) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108Paul M Barr, Hongli Li, Catherine Spier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
JAMA Network Open|January 19, 2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in ChildrenAndrea C Lo, Amy Liu, Qi Liu, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
Leukemia & Lymphoma|June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphomaDanielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood|February 3, 2023
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphomaJuan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, et al.
Pageof 30